Biotechs Turn to Digital Coins, Crypto to Boost Stock Prices

In a bid to boost their stock prices, some small biotech companies are turning to digital coins and cryptocurrency as a new strategy. These biotechs, which have largely missed out on the broader market's rally, are hoping that the association with the hype around cryptocurrencies will help generate investor interest and drive up their share prices. However, experts warn that this approach is risky and may not deliver the desired results. The biotech industry is highly specialized and requires significant investment in research and development, which is not necessarily compatible with the speculative nature of the cryptocurrency market. Furthermore, the use of digital coins and crypto by these companies raises concerns about their ability to focus on their core business and deliver meaningful medical advancements. The article cautions that this trend may be a distraction from the biotechs' primary mission of developing innovative treatments and therapies.